[Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].

Positionspapier der ÖGR und ÖGP zur Diagnose und Therapie der Sarkoidose 2024.

Austria Humans Rheumatology / standards Pulmonary Medicine / standards Sarcoidosis / therapy Practice Guidelines as Topic Sarcoidosis, Pulmonary / therapy Societies, Medical Evidence-Based Medicine

Cardiac magnetic resonance imaging Glucocorticosteroids Infliximab Kidney PET/CT

Journal

Wiener klinische Wochenschrift

ISSN: 1613-7671

Titre abrégé: Wien Klin Wochenschr

Pays: Austria

ID NLM: 21620870R

Informations de publication

Date de publication:
Oct 2024

Historique:

accepted: 28 08 2024

medline: 9 10 2024

pubmed: 9 10 2024

entrez: 9 10 2024

Statut: ppublish

Résumé

In many cases sarcoidosis is a multisystemic disease that requires interdisciplinary medical cooperation in the diagnostics, treatment and medical care during follow-up. Due to the often chronic course, it is of utmost importance to include patients with their priorities and wishes at an early stage and extensively in disease management and to establish a shared decision making whenever possible. In the process of writing this joint position paper, the expert group on interstitial and orphan lung diseases of the Austrian Society for Pulmonology and the working group on rheumatological lung disorders of the Austrian Society for Rheumatology and Rehabilitation sought to include patient advocacy groups as well as experts for rare organ manifestations of sarcoidosis. This position paper is not only meant to reflect current scientific and clinical standards but should also focus the national expertise and by networking and exchange to be a first step to strengthen cooperation between stakeholders to ultimately improve care for patients with sarcoidosis. Die Sarkoidose ist in vielen Fällen eine Multisystemerkrankung, die eine interdisziplinäre medizinische Zusammenarbeit in Diagnostik, Therapie und in der medizinischen Betreuung im Verlauf erfordert. Aufgrund des oft chronischen Verlaufes ist es besonders wichtig, Patientinnen und Patienten mit ihren Prioritäten und Wünschen frühzeitig und umfassend in die medizinische Betreuung einzubinden und, wenn möglich, ein „shared decision making“ zu etablieren. Beim Verfassen dieses gemeinsamen Positionspapieres war es der Expertengruppe für interstitielle Lungenerkrankungen und „orphan diseases“ der Österreichischen Gesellschaft für Pneumologie sowie der Arbeitsgruppe Rheuma und Lunge der Österreichischen Gesellschaft für Rheumatologie und Rehabilitation ein besonderes Anliegen, sowohl PatientInnenvertreter als auch ExpertInnen für seltenere Organmanifestationen der Sarkoidose einzubeziehen. Dieses Positionspapier soll nicht nur ein Spiegel der aktuellen klinischen und wissenschaftlichen Praxis sein, sondern auch die nationale Expertise bündeln und durch Vernetzung und Austausch ein erster Schritt zu einer Stärkung der Betreuungsstruktur von PatientInnen mit Sarkoidose sein.

Autres résumés

Type: Publisher (ger)

Die Sarkoidose ist in vielen Fällen eine Multisystemerkrankung, die eine interdisziplinäre medizinische Zusammenarbeit in Diagnostik, Therapie und in der medizinischen Betreuung im Verlauf erfordert. Aufgrund des oft chronischen Verlaufes ist es besonders wichtig, Patientinnen und Patienten mit ihren Prioritäten und Wünschen frühzeitig und umfassend in die medizinische Betreuung einzubinden und, wenn möglich, ein „shared decision making“ zu etablieren. Beim Verfassen dieses gemeinsamen Positionspapieres war es der Expertengruppe für interstitielle Lungenerkrankungen und „orphan diseases“ der Österreichischen Gesellschaft für Pneumologie sowie der Arbeitsgruppe Rheuma und Lunge der Österreichischen Gesellschaft für Rheumatologie und Rehabilitation ein besonderes Anliegen, sowohl PatientInnenvertreter als auch ExpertInnen für seltenere Organmanifestationen der Sarkoidose einzubeziehen. Dieses Positionspapier soll nicht nur ein Spiegel der aktuellen klinischen und wissenschaftlichen Praxis sein, sondern auch die nationale Expertise bündeln und durch Vernetzung und Austausch ein erster Schritt zu einer Stärkung der Betreuungsstruktur von PatientInnen mit Sarkoidose sein.

Identifiants

DOI: 10.1007/s00508-024-02444-z PMID: 39382646

pubmed: 39382646

doi: 10.1007/s00508-024-02444-z

pii: 10.1007/s00508-024-02444-z

doi:

Types de publication

English Abstract Journal Article

Langues

ger

Sous-ensembles de citation

Pagination

669-687

Informations de copyright

Références

Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J. 2018; https://doi.org/10.1183/13993003.00991-2017 .

doi: 10.1183/13993003.00991-2017

Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc. 2016;91(2):183–8. https://doi.org/10.1016/j.mayocp.2015.10.024 .

doi: 10.1016/j.mayocp.2015.10.024

Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45. https://doi.org/10.1038/s41572-019-0096-x .

doi: 10.1038/s41572-019-0096-x

Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med. 2021;385(11):1018–32. https://doi.org/10.1056/NEJMra2101555 .

doi: 10.1056/NEJMra2101555

Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020;26(5):527–34. https://doi.org/10.1097/MCP.0000000000000715 .

doi: 10.1097/MCP.0000000000000715

Prasse A. The diagnosis, differential diagnosis, and treatment of sarcoidosis. Dtsch Arztebl Int. 2016;113(33):565–74. https://doi.org/10.3238/arztebl.2016.0565 .

doi: 10.3238/arztebl.2016.0565 pmcid: 5015588

Baughman RP, Field S, Costabel U, et al. Sarcoidosis in america. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–52. https://doi.org/10.1513/AnnalsATS.201511-760OC .

doi: 10.1513/AnnalsATS.201511-760OC

Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26–e51. https://doi.org/10.1164/rccm.202002-0251ST .

doi: 10.1164/rccm.202002-0251ST pmcid: 7159433

Pagán AJ, Ramakrishnan L. The formation and function of granulomas. Annu Rev Immunol. 2018;36:639–65. https://doi.org/10.1146/annurev-immunol-032712-100022 .

doi: 10.1146/annurev-immunol-032712-100022

Meyer KC, Raghu G, Baughman RP, et al. An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14. https://doi.org/10.1164/rccm.201202-0320ST .

doi: 10.1164/rccm.201202-0320ST

Kraaijvanger R, Janssen Bonás M, Vorselaars ADM, Veltkamp M. Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects. Front Immunol. 2020;11:1443. https://doi.org/10.3389/fimmu.2020.01443 .

doi: 10.3389/fimmu.2020.01443 pmcid: 7372102

Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P‑Y, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155–67. https://doi.org/10.1016/S0140-6736(13)60680-7 .

doi: 10.1016/S0140-6736(13)60680-7

Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021;76(1):4–20. https://doi.org/10.1136/thoraxjnl-2019-214348 .

doi: 10.1136/thoraxjnl-2019-214348

Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis. 2013;30(2):113–20.

Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165–72. https://doi.org/10.1136/bmj.2.5261.1165 .

doi: 10.1136/bmj.2.5261.1165 pmcid: 1970202

Bandyopadhyay D, Mirsaeidi MS. Sarcoidosis-associated pulmonary fibrosis: joining the dots. Eur Respir Rev. 2023; https://doi.org/10.1183/16000617.0085-2023 .

doi: 10.1183/16000617.0085-2023 pmcid: 10523156

Desai SR, Sivarasan N, Johannson KA, et al. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study. Lancet Respir Med. 2023; https://doi.org/10.1016/S2213-2600(23)00267-9 .

doi: 10.1016/S2213-2600(23)00267-9

Judson MA. The management of sarcoidosis in the 2020s by the primary care physician. Am J Med. 2023;136(6):534–44. https://doi.org/10.1016/j.amjmed.2023.02.014 .

doi: 10.1016/j.amjmed.2023.02.014

Keijsers RGM, Grutters JC. In which patients with sarcoidosis is FDG PET/CT indicated? J Clin Med. 2020; https://doi.org/10.3390/jcm9030890 .

doi: 10.3390/jcm9030890 pmcid: 7141490

Treglia G, Annunziata S, Sobic-Saranovic D, Bertagna F, Caldarella C, Giovanella L. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. Acad Radiol. 2014;21(5):675–84. https://doi.org/10.1016/j.acra.2014.01.008 .

doi: 10.1016/j.acra.2014.01.008

Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9(3):e867. https://doi.org/10.1161/CIRCIMAGING.113.000867 .

doi: 10.1161/CIRCIMAGING.113.000867

Judson MA. Environmental risk factors for sarcoidosis. Front Immunol. 2020;11:1340. https://doi.org/10.3389/fimmu.2020.01340 .

doi: 10.3389/fimmu.2020.01340 pmcid: 7333358

Rossides M, Grunewald J, Eklund A, et al. Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. 2018; https://doi.org/10.1183/13993003.00385-2018 .

doi: 10.1183/13993003.00385-2018 pmcid: 5886843

Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91. https://doi.org/10.1164/ajrccm.164.11.2106001 .

doi: 10.1164/ajrccm.164.11.2106001

Linke M, Pham HTT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302. https://doi.org/10.1038/ni.3655 .

doi: 10.1038/ni.3655 pmcid: 5321578

Pacheco Y, Lim CX, Weichhart T, Valeyre D, Bentaher A, Calender A. Sarcoidosis and the mTOR, Rac1, and autophagy triad. Trends Immunol. 2020;41(4):286–99. https://doi.org/10.1016/j.it.2020.01.007 .

doi: 10.1016/j.it.2020.01.007

Pizzini A, Bacher H, Aichner M, et al. High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis. Respir Med. 2021;177:106294. https://doi.org/10.1016/j.rmed.2020.106294 .

doi: 10.1016/j.rmed.2020.106294

Bueno-Beti C, Lim CX, Protonotarios A, et al. An mTORC1-dependent mouse model for cardiac sarcoidosis. J Am Heart Assoc. 2023;12(19):e30478. https://doi.org/10.1161/JAHA.123.030478 .

doi: 10.1161/JAHA.123.030478 pmcid: 10727264

Baughman RP, Judson MA, Wells A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis. 2017;34(4):280–2. https://doi.org/10.36141/svdld.v34i4.6957 .

doi: 10.36141/svdld.v34i4.6957

Hu X, Carmona EM, Yi ES, Pellikka PA, Ryu J. Causes of death in patients with chronic sarcoidosis. Sarcoidosis. 2016;33(3):275–80.

Moor CC, van Manen MJG, van Hagen PM, et al. Needs, perceptions and education in sarcoidosis: a live interactive survey of patients and partners. Lung. 2018;196(5):569–75. https://doi.org/10.1007/s00408-018-0144-4 .

doi: 10.1007/s00408-018-0144-4 pmcid: 6153596

Baughman RP, Barriuso R, Beyer K, et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018; https://doi.org/10.1183/23120541.00141-2018 .

doi: 10.1183/23120541.00141-2018 pmcid: 6302206

Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King’s sarcoidosis questionnaire for the assessment of health status. Thorax. 2013;68(1):57–65. https://doi.org/10.1136/thoraxjnl-2012-201962 .

doi: 10.1136/thoraxjnl-2012-201962

Drent M, Costabel U, Crouser ED, Grunewald J, Bonella F. Misconceptions regarding symptoms of sarcoidosis. Lancet Respir Med. 2021;9(8):816–8. https://doi.org/10.1016/S2213-2600(21)00311-8 .

doi: 10.1016/S2213-2600(21)00311-8

Bosse-Henck A, Wirtz H, Hinz A. Organ manifestation and subjective sleep quality in sarcoidosis. Pneumologie. 2016;70(8):522–9. https://doi.org/10.1055/s-0042-100554 .

doi: 10.1055/s-0042-100554

Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study. Respir Med. 2018;138:S24–S30. https://doi.org/10.1016/j.rmed.2017.11.008 .

doi: 10.1016/j.rmed.2017.11.008

Moor CC, Kahlmann V, Culver DA, Wijsenbeek MS. Comprehensive care for patients with sarcoidosis. J Clin Med. 2020; https://doi.org/10.3390/jcm9020390 .

doi: 10.3390/jcm9020390 pmcid: 7074134

Saketkoo LA, Russell A‑M, Jensen K, et al. Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes. Diagnostics. 2021; https://doi.org/10.3390/diagnostics11061089 .

doi: 10.3390/diagnostics11061089 pmcid: 8232334

Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest. 2018;153(1):105–13. https://doi.org/10.1016/j.chest.2017.07.008 .

doi: 10.1016/j.chest.2017.07.008

Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021; https://doi.org/10.1183/13993003.04079-2020 .

doi: 10.1183/13993003.04079-2020

Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–30. https://doi.org/10.1164/rccm.201010-1679OC .

doi: 10.1164/rccm.201010-1679OC pmcid: 3137141

Trivieri MG, Spagnolo P, Birnie D, et al. Challenges in cardiac and pulmonary sarcoidosis. J Am Coll Cardiol. 2020;76(16):1878–901. https://doi.org/10.1016/j.jacc.2020.08.042 .

doi: 10.1016/j.jacc.2020.08.042 pmcid: 7808240

Belperio JA, Shaikh F, Abtin FG, et al. Diagnosis and treatment of pulmonary sarcoidosis: a review. JAMA. 2022;327(9):856–67.

doi: 10.1001/jama.2022.1570

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402. https://doi.org/10.1016/S2213-2600(18)30064-X .

doi: 10.1016/S2213-2600(18)30064-X

Huitema MP, Mathijssen H, Mager JJ, Snijder RJ, Grutters JC, Post MC. Sarcoidosis-associated pulmonary hypertension. Semin Respir Crit Care Med. 2020;41(5):659–72. https://doi.org/10.1055/s-0040-1713615 .

doi: 10.1055/s-0040-1713615

Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med. 2017;132:9–14. https://doi.org/10.1016/j.rmed.2017.09.003 .

doi: 10.1016/j.rmed.2017.09.003

Dhooria S, Sehgal IS, Agarwal R, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J. 2023; https://doi.org/10.1183/13993003.00198-2023 .

doi: 10.1183/13993003.00198-2023 pmcid: 10060665

Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020; https://doi.org/10.1183/16000617.0146-2019 .

doi: 10.1183/16000617.0146-2019 pmcid: 9489143

Humphrey MB, Russell L, Danila MI, et al. 2022 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2023;75(12):2088–102. https://doi.org/10.1002/art.42646 .

doi: 10.1002/art.42646

Baughman RP, Cremers JP, Harmon M, Lower EE, Drent M. Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. Sarcoidosis. 2020;37(3):e2020001. https://doi.org/10.36141/svdld.v37i3.9362 .

doi: 10.36141/svdld.v37i3.9362

Pande A, Culver DA. Knowing when to use steroids, immunosuppressants or biologics for the treatment of sarcoidosis. Expert Rev Respir Med. 2020;14(3):285–98. https://doi.org/10.1080/17476348.2020.1707672 .

doi: 10.1080/17476348.2020.1707672

Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802. https://doi.org/10.1164/rccm.200603-402OC .

doi: 10.1164/rccm.200603-402OC

Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis. 2014;31(1):46–54.

Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27. https://doi.org/10.1056/NEJMoa1908681 .

doi: 10.1056/NEJMoa1908681

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. https://doi.org/10.1164/rccm.202202-0399ST .

doi: 10.1164/rccm.202202-0399ST pmcid: 9851481

Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022;13(1):3140. https://doi.org/10.1038/s41467-022-30615-x .

doi: 10.1038/s41467-022-30615-x pmcid: 9170782

Wang A, Rahman N‑T, McGeary MK, et al. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. J Allergy Clin Immunol. 2021;147(5):1795–809. https://doi.org/10.1016/j.jaci.2020.10.012 .

doi: 10.1016/j.jaci.2020.10.012

Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol. 2020;2(2):106–9. https://doi.org/10.1002/acr2.11112 .

doi: 10.1002/acr2.11112 pmcid: 7011417

Liu J, Ma P, Lai L, et al. Transcriptional and immune landscape of cardiac sarcoidosis. Circ Res. 2022;131(8):654–69. https://doi.org/10.1161/CIRCRESAHA.121.320449 .

doi: 10.1161/CIRCRESAHA.121.320449 pmcid: 9514756

Lim CX, Redl A, Kleissl L, et al. Aberrant lipid metabolism in macrophages is associated with granuloma formation in sarcoidosis. Am J Respir Crit Care Med. 2024; https://doi.org/10.1164/rccm.202307-1273OC .

doi: 10.1164/rccm.202307-1273OC

Redl A, Doberer K, Unterluggauer L, et al. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial. Lancet Rheumatol. 2024;6(2):e81–e91. https://doi.org/10.1016/S2665-9913(23)00302-8 .

doi: 10.1016/S2665-9913(23)00302-8

Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with sirolimus in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2020;202(9):e119–e20. https://doi.org/10.1164/rccm.202004-0914IM .

doi: 10.1164/rccm.202004-0914IM

Lee GM, Pope K, Meek L, Chung JH, Hobbs SB, Walker CM. Sarcoidosis: a diagnosis of exclusion. AJR Am J Roentgenol. 2020;214(1):50–8. https://doi.org/10.2214/AJR.19.21436 .

doi: 10.2214/AJR.19.21436

Kollert F, Geck B, Suchy R, et al. The impact of gas exchange measurement during exercise in pulmonary sarcoidosis. Respir Med. 2011;105(1):122–9. https://doi.org/10.1016/j.rmed.2010.09.007 .

doi: 10.1016/j.rmed.2010.09.007

Esteves TC, Aparicio G, Ferrer B, Garcia-Patos V. Prognostic value of skin lesions in sarcoidosis: clinical and histopathological clues. Eur J Dermatol. 2015;25(6):556–62. https://doi.org/10.1684/ejd.2015.2666 .

doi: 10.1684/ejd.2015.2666

Caplan A, Rosenbach M, Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):689–99. https://doi.org/10.1055/s-0040-1713130 .

doi: 10.1055/s-0040-1713130

Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699.e1–699.18. https://doi.org/10.1016/j.jaad.2011.11.965 . quiz 717–718.

doi: 10.1016/j.jaad.2011.11.965

Giner T, Benoit S, Kneitz H, Goebeler M. Sarcoidosis : dermatological view of a rare multisystem disease. Hautarzt. 2017;68(7):526–35. https://doi.org/10.1007/s00105-017-4005-5 .

doi: 10.1007/s00105-017-4005-5

Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):463–73. https://doi.org/10.1055/s-0030-1262214 .

doi: 10.1055/s-0030-1262214 pmcid: 3314339

Bechman K, Christidis D, Walsh S, Birring SS, Galloway J. A review of the musculoskeletal manifestations of sarcoidosis. Rheumatology. 2018;57(5):777–83. https://doi.org/10.1093/rheumatology/kex317 .

doi: 10.1093/rheumatology/kex317

Kobak S. Sarcoidosis: a rheumatologist’s perspective. Ther Adv Musculoskelet Dis. 2015;7(5):196–205. https://doi.org/10.1177/1759720X15591310 .

doi: 10.1177/1759720X15591310 pmcid: 4572362

Hammam N, Evans M, Morgan E, et al. Treatment of sarcoidosis in US rheumatology practices: data from the American college of rheumatology’s rheumatology Informatics system for effectiveness (RISE) registry. Arthritis Care Res. 2022;74(3):371–6. https://doi.org/10.1002/acr.24496 .

doi: 10.1002/acr.24496

Lofgren S. Primary pulmonary sarcoidosis. I. Early signs and symptoms. Acta Med Scand. 1953;145(6):424–31.

doi: 10.1111/j.0954-6820.1953.tb07039.x

Visser H, Vos K, Zanelli E, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis. 2002;61(6):499–504. https://doi.org/10.1136/ard.61.6.499 .

doi: 10.1136/ard.61.6.499 pmcid: 1754119

Glennås A, Kvien TK, Melby K, et al. Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome. Br J Rheumatol. 1995;34(1):45–50. https://doi.org/10.1093/rheumatology/34.1.45 .

doi: 10.1093/rheumatology/34.1.45

Mañá J, Gómez-Vaquero C, Montero A, et al. Löfgren’s syndrome revisited: a study of 186 patients. Am J Med. 1999;107(3):240–5. https://doi.org/10.1016/s0002-9343(99)00223-5 .

doi: 10.1016/s0002-9343(99)00223-5

Abril A, Cohen MD. Rheumatologic manifestations of sarcoidosis. Curr Opin Rheumatol. 2004;16(1):51–5. https://doi.org/10.1097/00002281-200401000-00010 .

doi: 10.1097/00002281-200401000-00010

Boyaci B, Hornicek F, Rosenthal D, et al. Sarcoidosis of the spine: a report of five cases and a review of the literature. J Bone Joint Surg Am. 2012;94(7):e42. https://doi.org/10.2106/JBJS.K.00062 .

doi: 10.2106/JBJS.K.00062

Kobak S, Sever F, Ince O, Orman M. The prevalence of sacroiliitis and spondyloarthritis in patients with sarcoidosis. Int J Rheumatol. 2014;2014:289454. https://doi.org/10.1155/2014/289454 .

doi: 10.1155/2014/289454 pmcid: 4037117

Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol. 2003;17(6):971–87. https://doi.org/10.1016/j.berh.2003.09.005 .

doi: 10.1016/j.berh.2003.09.005

Pitt P, Hamilton EB, Innes EH, Morley KD, Monk BE, Hughes GR. Sarcoid dactylitis. Ann Rheum Dis. 1983;42(6):634–9. https://doi.org/10.1136/ard.42.6.634 .

doi: 10.1136/ard.42.6.634 pmcid: 1001318

Aptel S, Lecocq-Teixeira S, Olivier P, Regent D, Teixeira PG, Blum A. Multimodality evaluation of musculoskeletal sarcoidosis: Imaging findings and literature review. Diagn Interv Imaging. 2016;97(1):5–18. https://doi.org/10.1016/j.diii.2014.11.038 .

doi: 10.1016/j.diii.2014.11.038

Silverstein A, Siltzbach LE. Muscle involvement in sarcoidosis. Asymptomatic, myositis, and myopathy. Arch Neurol. 1969;21(3):235–41. https://doi.org/10.1001/archneur.1969.00480150025002 .

doi: 10.1001/archneur.1969.00480150025002

Ten Dam L, Raaphorst J, van der Kooi AJ, et al. Clinical characteristics and outcome in muscular sarcoidosis: a retrospective cohort study and literature review. Neuromuscul Disord. 2022;32(7):557–63. https://doi.org/10.1016/j.nmd.2022.05.012 .

doi: 10.1016/j.nmd.2022.05.012

Marcellis RGJ, Lenssen AF, Elfferich MDP, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38(3):628–34.

doi: 10.1183/09031936.00117710

Rosenbaum JT, Pasadhika S. Ocular sarcoidosis. Clin Chest Med. 2024;45(1):59–70. https://doi.org/10.1016/j.ccm.2023.08.003 .

doi: 10.1016/j.ccm.2023.08.003

Giorgiutti S, Jacquot R, El Jammal T, et al. Sarcoidosis-related uveitis: a review. J Clin Med. 2023; https://doi.org/10.3390/jcm12093194 .

doi: 10.3390/jcm12093194 pmcid: 10178951

Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA. Revised criteria of international workshop on ocular sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(10):1418–22. https://doi.org/10.1136/bjophthalmol-2018-313356 .

doi: 10.1136/bjophthalmol-2018-313356

Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for UveitiS (FOCUS) initiative. Ophthalmology. 2018;125(5):757–73. https://doi.org/10.1016/j.ophtha.2017.11.017 .

doi: 10.1016/j.ophtha.2017.11.017

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731. https://doi.org/10.1093/eurheartj/ehac237 .

doi: 10.1093/eurheartj/ehac237

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023; https://doi.org/10.1183/13993003.00879-2022 .

doi: 10.1183/13993003.00879-2022 pmcid: 10512088

Savale L, Huitema M, Shlobin O, et al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev. 2022; https://doi.org/10.1183/16000617.0165-2021 .

doi: 10.1183/16000617.0165-2021 pmcid: 8924706

Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017; https://doi.org/10.1183/13993003.00465-2017 .

doi: 10.1183/13993003.00465-2017

Bandyopadhyay D, Humbert M. An update on sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med. 2020;26(5):582–90. https://doi.org/10.1097/MCP.0000000000000701 .

doi: 10.1097/MCP.0000000000000701

Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145(4):810–7. https://doi.org/10.1378/chest.13-1766 .

doi: 10.1378/chest.13-1766

Baughman RP, Shlobin OA, Gupta R, et al. Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year double-blind, placebo-controlled trial. Chest. 2022;161(2):448–57. https://doi.org/10.1016/j.chest.2021.07.2162 .

doi: 10.1016/j.chest.2021.07.2162

Le Pavec J, Valeyre D, Gazengel P, et al. Lung transplantation for sarcoidosis: outcome and prognostic factors. Eur Respir J. 2021; https://doi.org/10.1183/13993003.03358-2020 .

doi: 10.1183/13993003.03358-2020

. A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation & infection committees of the European association of nuclear medicine, the European association of cardiovascular imaging, and the American. Eur Heart J Cardiovasc Imaging. 2017;18(10):1073–89. https://doi.org/10.1093/ehjci/jex146 .

Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–21. https://doi.org/10.1016/j.jacc.2016.03.605 .

doi: 10.1016/j.jacc.2016.03.605

Seferović PM, Tsutsui H, McNamara DM, et al. Heart failure association of the ESC, heart failure society of america and Japanese heart failure society position statement on endomyocardial biopsy. Eur J Heart Fail. 2021;23(6):854–71. https://doi.org/10.1002/ejhf.2190 .

doi: 10.1002/ejhf.2190

Liang JJ, Hebl VB, DeSimone CV, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2(5):466–73. https://doi.org/10.1016/j.jchf.2014.03.015 .

doi: 10.1016/j.jchf.2014.03.015 pmcid: 4459501

Vaidya VR, Abudan AA, Vasudevan K, et al. The efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic review. J Interv Card Electrophysiol. 2018;53(1):63–71. https://doi.org/10.1007/s10840-018-0410-7 .

doi: 10.1007/s10840-018-0410-7

Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–626. https://doi.org/10.1093/eurheartj/ehad194 .

doi: 10.1093/eurheartj/ehad194

Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–23. https://doi.org/10.1016/j.hrthm.2014.03.043 .

doi: 10.1016/j.hrthm.2014.03.043

Slart RHJA, Glaudemans AWJM, Gheysens O, et al. Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summary. Eur Heart J Cardiovasc Imaging. 2020;21(12):1320–30. https://doi.org/10.1093/ehjci/jeaa299 .

doi: 10.1093/ehjci/jeaa299 pmcid: 7695243

Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141(1):154–62. https://doi.org/10.1378/chest.11-0263 .

doi: 10.1378/chest.11-0263

Skowasch D, Bonella F, Buschulte K, et al. Therapeutic pathways in sarcoidosisA position paper of the German society of respiratory medicine (DGP). Pneumologie. 2024;78(3):151–66. https://doi.org/10.1055/a-2259-1046 .

doi: 10.1055/a-2259-1046

Bergner R, Weiner SM, Kehl G, et al. Renal disease in sarcoidosis patients in a German multicentric retrospective cohort study. Respir Med. 2023;209:107121. https://doi.org/10.1016/j.rmed.2023.107121 .

doi: 10.1016/j.rmed.2023.107121

Gorsane I, Zammouri A, Hajji M, et al. Renal involvement in sarcoidosis: prognostic and predictive factors. Nephrol Ther. 2022;18(1):52–8. https://doi.org/10.1016/j.nephro.2021.08.001 .

doi: 10.1016/j.nephro.2021.08.001

Warshauer DM, Lee JKT. Imaging manifestations of abdominal sarcoidosis. AJR Am J Roentgenol. 2004;182(1):15–28. https://doi.org/10.2214/ajr.182.1.1820015 .

doi: 10.2214/ajr.182.1.1820015

Bergner R, Löffler C. Renal sarcoidosis: approach to diagnosis and management. Curr Opin Pulm Med. 2018;24(5):513–20. https://doi.org/10.1097/MCP.0000000000000504 .

doi: 10.1097/MCP.0000000000000504

Mehta S, Lightle A, Judson MA. Renal sarcoidosis. Nephrol Dial Transplant. 2023;38(4):803–10. https://doi.org/10.1093/ndt/gfac219 .

doi: 10.1093/ndt/gfac219

Mahévas M, Lescure FX, Boffa J‑J, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine. 2009;88(2):98–106. https://doi.org/10.1097/MD.0b013e31819de50f .

doi: 10.1097/MD.0b013e31819de50f

Hilderson I, Van Laecke S, Wauters A, Donck J. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrol Dial Transplant. 2014;29(10):1841–7. https://doi.org/10.1093/ndt/gft442 .

doi: 10.1093/ndt/gft442

Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220. https://doi.org/10.1186/s12883-016-0741-x .

doi: 10.1186/s12883-016-0741-x pmcid: 5109654

Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. Neurol Neuroimmunol Neuroinflamm. 2021; https://doi.org/10.1212/NXI.0000000000001084 .

doi: 10.1212/NXI.0000000000001084 pmcid: 8495503

Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449–60. https://doi.org/10.1093/qjmed/hcp042 .

doi: 10.1093/qjmed/hcp042

Lexa FJ, Grossman RI. MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. AJNR Am J Neuroradiol. 1994;15(5):973–82.

pmcid: 8332168

Vlad B, Neidhart S, Hilty M, Ziegler M, Jelcic I. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction. Front Neurol. 2023;14:1135392. https://doi.org/10.3389/fneur.2023.1135392 .

doi: 10.3389/fneur.2023.1135392 pmcid: 10080049

Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020;2:16. https://doi.org/10.1186/s42466-020-00063-3 .

doi: 10.1186/s42466-020-00063-3 pmcid: 7650069

Shah N, Mitra A. Gastrointestinal and hepatic sarcoidosis: a review article. Clin Liver Dis. 2021;17(4):301–7. https://doi.org/10.1002/cld.1055 .

doi: 10.1002/cld.1055

Brito-Zerón P, Bari K, Baughman RP, Ramos-Casals M. Sarcoidosis involving the gastrointestinal tract: diagnostic and therapeutic management. Am J Gastroenterol. 2019;114(8):1238–47. https://doi.org/10.14309/ajg.0000000000000171 .

doi: 10.14309/ajg.0000000000000171

Vahid B, Spodik M, Braun KN, Ghazi LJ, Esmaili A. Sarcoidosis of gastrointestinal tract: a rare disease. Dig Dis Sci. 2007;52(12):3316–20. https://doi.org/10.1007/s10620-006-9448-y .

doi: 10.1007/s10620-006-9448-y

Ghrenassia E, Mekinian A, Chapelon-Albric C, et al. Digestive-tract sarcoidosis: French nationwide case-control study of 25 cases. Medicine. 2016;95(29):e4279. https://doi.org/10.1097/MD.0000000000004279 .

doi: 10.1097/MD.0000000000004279 pmcid: 5265782

Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):83–101. https://doi.org/10.1055/s-2007-970335 .

doi: 10.1055/s-2007-970335

. EASL clinical practice guidelines: management of cholestatic liver diseases. j Hepatol. 2009;51(2):237–67. https://doi.org/10.1016/j.jhep.2009.04.009 .

Scott GC, Berman JM, Higgins JLJ. CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. J Comput Assist Tomogr. 1997;21(3):369–72. https://doi.org/10.1097/00004728-199705000-00006 .

doi: 10.1097/00004728-199705000-00006

Choi E‑YK, Lamps LW. Granulomas in the liver, with a focus on infectious causes. Surg Pathol Clin. 2018;11(2):231–50. https://doi.org/10.1016/j.path.2018.02.008 .

doi: 10.1016/j.path.2018.02.008

Alenezi B, Lamoureux E, Alpert L, Szilagyi A. Effect of ursodeoxycholic acid on granulomatous liver disease due to sarcoidosis. Dig Dis Sci. 2005;50(1):196–200. https://doi.org/10.1007/s10620-005-1300-2 .

doi: 10.1007/s10620-005-1300-2

Bakker GJ, Haan YCL, Maillette de Buy Wenniger LJ, Beuers U. Sarcoidosis of the liver: to treat or not to treat? Neth J Med. 2012;70(8):349–56.

Cremers JP, Drent M, Baughman RP, Wijnen PA, Koek GH. Therapeutic approach of hepatic sarcoidosis. Curr Opin Pulm Med. 2012;18(5):472–82. https://doi.org/10.1097/MCP.0b013e3283541626 .

doi: 10.1097/MCP.0b013e3283541626

Strookappe B, Saketkoo LA, Elfferich M, et al. Physical activity and training in sarcoidosis: review and experience-based recommendations. Expert Rev Respir Med. 2016;10(10):1057–68. https://doi.org/10.1080/17476348.2016.1227244 .

doi: 10.1080/17476348.2016.1227244

Lingner H, Buhr-Schinner H, Hummel S, et al. Short-term effects of a multimodal 3‑week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study. Respiration. 2018;95(5):343–53. https://doi.org/10.1159/000486964 .

doi: 10.1159/000486964

Wallaert B, Kyheng M, Labreuche J, Stelianides S, Wemeau L, Grosbois JM. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: a randomized controlled trial. Respir Med Res. 2020;77:1–7. https://doi.org/10.1016/j.resmer.2019.10.003 .

doi: 10.1016/j.resmer.2019.10.003

Gloeckl R, Zwick RH, Fürlinger U, et al. Prescribing and adjusting exercise training in chronic respiratory diseases—expert-based practical recommendations. Pulmonology. 2023;29(4):306–14. https://doi.org/10.1016/j.pulmoe.2022.09.004 .

doi: 10.1016/j.pulmoe.2022.09.004

Luu B, Gupta A, Fabiano N, et al. Influence of pulmonary rehabilitation on symptoms of anxiety and depression in interstitial lung disease: a systematic review of randomized controlled trials. Respir Med. 2023;219:107433. https://doi.org/10.1016/j.rmed.2023.107433 .

doi: 10.1016/j.rmed.2023.107433

European Association of Patients Organizations of Sarcoidosis and other Granulomatous Disorders (EPOS). EURORDIS sarcoidosis patient journey. 2021. https://ern-lung.eu/wp-content/uploads/2021/01/Sarc-PJ-Final.jpg ..

Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of sarcoidosis. Clin Chest Med. 2015;36(4):727–37. https://doi.org/10.1016/j.ccm.2015.08.013 .

doi: 10.1016/j.ccm.2015.08.013

Voortman M, Hendriks CMR, Elfferich MDP, et al. The burden of sarcoidosis symptoms from a patient perspective. Lung. 2019;197(2):155–61.

doi: 10.1007/s00408-019-00206-7 pmcid: 6486948

Hendriks CMR, Saketkoo LA, Elfferich MDP, De Vries J, Wijnen PAHM, Drent M. Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability. Lung. 2019;197(4):407–13. https://doi.org/10.1007/s00408-019-00234-3 .

doi: 10.1007/s00408-019-00234-3 pmcid: 6647075

European Lung Foundation. Sarcoidosis patient priorities. https://europeanlunginfo.org/sarcoidosis/library/ ..

Hutchinson J. Anomalous diseases of skin and fingers. Illus Clin Surg. 1877; https://doi.org/10.2307/j.ctt9qh7zv.35 .

doi: 10.2307/j.ctt9qh7zv.35

Baughman RP, Scholand MB, Rahaghi FF. Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev. 2020; https://doi.org/10.1183/16000617.0145-2019 .

doi: 10.1183/16000617.0145-2019 pmcid: 9489143